Full Press Release Details
CF602 Sexual Dysfunction Drug Backed by New Preclinical Data
Progresses Towards an IND
Company aims to file an IND with the FDA to allow the initiation of a Phase I clinical study
Israel, June 29, 2015 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary
small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing pre-clinical
program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S.
Food and Drug Administration to allow the initiation of a Phase I clinical study.
pre-clinical studies, the Company established CF602's efficacy in a diabetic rat pre-clinical study. The animals were treated
twice daily with CF602 for a period of 1 and 5 days. The results demonstrated a significant response rate resulting in a 188%
(p<0.01) and 250% (p<0.001) increase in penial intra-cavernosal pressure (ICP), respectively compared to placebo. CF602
was shown not to affect blood pressure in this model.
studies to date, utilizing newly manufactured CF602 drug substance, have demonstrated good bioavailability and linear pharmacokinetics.
data resulting from the progress in our pre-clinical studies strengthen our belief that CF602 is a strong drug candidate to be
developed for people suffering from sexual dysfunction. We have a robust intellectual property portfolio which includes an issued
composition of matter patent and other pending patent applications protecting the use of CF602 for sexual dysfunction,"
stated Can-Fite CEO Dr. Pnina Fishman.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's CF101
is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid
arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the
U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate,
and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date.
For more information please visit: www.can-fite.com
release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things,
its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from
time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry
sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information,
future events or otherwise.